lupus nephritis

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of Lupkynis (voclosporin) for active lupus nephritis. Lupus is an autoimmune disease. It causes the immune system to produce...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis. Data will be presented at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2021...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN). The study results demonstrated that Lupkynis combined with mycophenolate mofetil (MMF) and low-...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has presented additional efficacy data from the AURA-LV and AURORA 1 trials of Lupkynis (voclosporin) in lupus nephritis (LN). Aurinia shared the data at the National Kidney Foundation 2021 Spring Clinical Meeting. Pooled data...

Shares of small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) are on a tear after the company reported positive clinical readout for its lead asset voclosporin in treating lupus nephritis, an autoimmune disorder. Aurinia has a single-product pipeline. Voclosporin is being evaluated for...

Shares of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), a clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity, ticked higher by more than 3 percent early Friday morning after the company presented results from an ongoing study. Aurinia presented remission...

Elemer Piros of Cantor Fitzgerald maintains an Overweight rating on Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s stock with a $14 price target after the company reported data from a Phase 2b study, which helped boost the stock higher by more than 5 percent. During the National Kidney Foundation...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...